SG11201402876UA - Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof - Google Patents
Quinolylpyrrolopyrimidyl fused-ring compound or salt thereofInfo
- Publication number
- SG11201402876UA SG11201402876UA SG11201402876UA SG11201402876UA SG11201402876UA SG 11201402876U A SG11201402876U A SG 11201402876UA SG 11201402876U A SG11201402876U A SG 11201402876UA SG 11201402876U A SG11201402876U A SG 11201402876UA SG 11201402876U A SG11201402876U A SG 11201402876UA
- Authority
- SG
- Singapore
- Prior art keywords
- quinolylpyrrolopyrimidyl
- fused
- salt
- ring compound
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012037565 | 2012-02-23 | ||
| PCT/JP2013/054615 WO2013125709A1 (en) | 2012-02-23 | 2013-02-22 | Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201402876UA true SG11201402876UA (en) | 2014-12-30 |
Family
ID=49005885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201402876UA SG11201402876UA (en) | 2012-02-23 | 2013-02-22 | Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8889666B2 (en) |
| EP (1) | EP2722332B1 (en) |
| JP (1) | JP5557963B2 (en) |
| KR (1) | KR101660145B1 (en) |
| CN (1) | CN104136438B (en) |
| CA (1) | CA2861980C (en) |
| DK (1) | DK2722332T3 (en) |
| ES (1) | ES2580530T3 (en) |
| HK (1) | HK1202862A1 (en) |
| HU (1) | HUE029343T2 (en) |
| MX (1) | MX351863B (en) |
| PL (1) | PL2722332T3 (en) |
| RU (1) | RU2581039C1 (en) |
| SG (1) | SG11201402876UA (en) |
| TW (1) | TWI496783B (en) |
| WO (1) | WO2013125709A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014129596A1 (en) * | 2013-02-22 | 2014-08-28 | 大鵬薬品工業株式会社 | Method for producing tricyclic compound, and tricyclic compound capable of being produced by said production method |
| PT3037424T (en) | 2013-08-22 | 2017-12-18 | Taiho Pharmaceutical Co Ltd | Novel quinoline-substituted compound |
| CN107406455B (en) * | 2015-03-31 | 2020-05-12 | 大鹏药品工业株式会社 | 3, 5-disubstituted phenylalkynyl compound crystal |
| WO2017064558A1 (en) * | 2015-10-14 | 2017-04-20 | 大鵬薬品工業株式会社 | Novel immunostimulant |
| JOP20190073A1 (en) * | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | Selective inhibitor of exon 20 insertion mutant egfr |
| CN108101905A (en) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | Pyrimido [5,4-b] indolizine or pyrimido [5,4-b] pyrrole biopterin compound, preparation method and the usage |
| TWI838345B (en) | 2017-09-01 | 2024-04-11 | 日商大鵬藥品工業股份有限公司 | Selective inhibitors for exon 18 and/or exon 21 mutant EGFR |
| CN115181104A (en) * | 2019-09-29 | 2022-10-14 | 深圳市塔吉瑞生物医药有限公司 | Substituted fused tricyclic derivatives, compositions and uses thereof |
| WO2022121967A1 (en) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr tyrosine kinase inhibitor and uses thereof |
| AU2022257621A1 (en) | 2021-04-13 | 2023-11-23 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| CN115785107B (en) * | 2022-12-15 | 2024-11-12 | 南京雷正医药科技有限公司 | A substituted 8,9-dihydropyrimido[5,4-b]indolizine compound, pharmaceutical composition and use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2601766A1 (en) * | 2005-03-17 | 2006-09-28 | Novartis Ag | N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
| US20080299113A1 (en) * | 2005-12-19 | 2008-12-04 | Arnold Lee D | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents |
| DK2004654T3 (en) * | 2006-04-04 | 2013-07-22 | Univ California | Pyrazolopyrimidine derivatives for use as kinase antagonists |
| WO2008018881A1 (en) * | 2006-08-10 | 2008-02-14 | Osi Pharmaceuticals, Inc. | 6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors |
| HUE025459T2 (en) * | 2006-09-22 | 2016-05-30 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| EP2543375A1 (en) * | 2007-03-28 | 2013-01-09 | Pharmacyclics, Inc. | Pyrrolo-pyrimidine analogues as inhibitors of bruton's tyrosine kinase |
| US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| CN102146059A (en) * | 2010-02-08 | 2011-08-10 | 上海艾力斯医药科技有限公司 | Quinazoline derivatives and preparation method and application thereof |
| NZ605988A (en) * | 2010-06-23 | 2014-11-28 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
| SG10201508958WA (en) * | 2010-11-01 | 2015-11-27 | Celgene Avilomics Res Inc | Heterocyclic Compounds And Uses Thereof |
-
2013
- 2013-02-22 WO PCT/JP2013/054615 patent/WO2013125709A1/en active Application Filing
- 2013-02-22 CN CN201380010586.3A patent/CN104136438B/en not_active Expired - Fee Related
- 2013-02-22 US US13/984,299 patent/US8889666B2/en not_active Expired - Fee Related
- 2013-02-22 EP EP13745327.0A patent/EP2722332B1/en not_active Not-in-force
- 2013-02-22 ES ES13745327.0T patent/ES2580530T3/en active Active
- 2013-02-22 SG SG11201402876UA patent/SG11201402876UA/en unknown
- 2013-02-22 RU RU2014138263/04A patent/RU2581039C1/en not_active IP Right Cessation
- 2013-02-22 PL PL13745327.0T patent/PL2722332T3/en unknown
- 2013-02-22 CA CA2861980A patent/CA2861980C/en not_active Expired - Fee Related
- 2013-02-22 TW TW102106272A patent/TWI496783B/en not_active IP Right Cessation
- 2013-02-22 JP JP2013534872A patent/JP5557963B2/en not_active Expired - Fee Related
- 2013-02-22 MX MX2014009991A patent/MX351863B/en active IP Right Grant
- 2013-02-22 KR KR1020147024020A patent/KR101660145B1/en not_active Expired - Fee Related
- 2013-02-22 HU HUE13745327A patent/HUE029343T2/en unknown
- 2013-02-22 DK DK13745327.0T patent/DK2722332T3/en active
-
2015
- 2015-04-02 HK HK15103353.8A patent/HK1202862A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK2722332T3 (en) | 2016-06-20 |
| CA2861980C (en) | 2016-11-08 |
| JPWO2013125709A1 (en) | 2015-07-30 |
| MX2014009991A (en) | 2014-09-08 |
| TW201339160A (en) | 2013-10-01 |
| WO2013125709A1 (en) | 2013-08-29 |
| MX351863B (en) | 2017-10-30 |
| PL2722332T3 (en) | 2016-10-31 |
| KR101660145B1 (en) | 2016-09-26 |
| CN104136438A (en) | 2014-11-05 |
| US20140057899A1 (en) | 2014-02-27 |
| US8889666B2 (en) | 2014-11-18 |
| TWI496783B (en) | 2015-08-21 |
| HUE029343T2 (en) | 2017-02-28 |
| EP2722332A4 (en) | 2014-04-23 |
| RU2581039C1 (en) | 2016-04-10 |
| EP2722332A1 (en) | 2014-04-23 |
| CN104136438B (en) | 2016-04-06 |
| EP2722332B1 (en) | 2016-04-20 |
| AU2013223052A1 (en) | 2014-07-03 |
| ES2580530T3 (en) | 2016-08-24 |
| CA2861980A1 (en) | 2013-08-29 |
| KR20140117647A (en) | 2014-10-07 |
| HK1202862A1 (en) | 2015-10-09 |
| JP5557963B2 (en) | 2014-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273276A (en) | Salt crystals | |
| EP2842955A4 (en) | Trk-INHIBITING COMPOUND | |
| HK1188451A1 (en) | Imidazo-oxazine compound or salt thereof | |
| AP2014007810A0 (en) | Imidazopyrrolidinone compounds | |
| GB201209138D0 (en) | Compounds | |
| GB201214750D0 (en) | Compounds | |
| GB201215357D0 (en) | Compounds | |
| HK1202862A1 (en) | Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof | |
| EP2828262A4 (en) | Imidazotriazinone compounds | |
| HK1199730A1 (en) | Piperidine compound or salt thereof | |
| GB201220843D0 (en) | Compound | |
| GB201204985D0 (en) | Compounds | |
| GB201204125D0 (en) | Compounds | |
| SI2836495T1 (en) | Tetrahydropyrrolothiazine compounds | |
| HK1185079A1 (en) | Novel bicyclic compound or salt thereof | |
| GB201209096D0 (en) | Compounds | |
| HK1215571A1 (en) | Cobicostat dichlohydrate salt | |
| GB201219820D0 (en) | Compounds | |
| GB201215675D0 (en) | Compound | |
| GB201216309D0 (en) | Compound | |
| GB201217310D0 (en) | Compounds | |
| GB201216448D0 (en) | Compound | |
| AU2013223052B2 (en) | Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof | |
| GB201222716D0 (en) | Compound | |
| GB201223429D0 (en) | Compounds |